News

Release Date:2/27/2023 9:08:00 PM

Within the low tissue absorption window, shifting to longer excitation wavelengths reduces tissue scattering and boosts penetration depth. Recently, the 2200 nm excitation window has emerged as the last and longest window suitable for deep-brain MPM. However, multiphoton fluorescence imaging at this window has not been demonstrated, due to the lack of characterization of multiphoton properties of fluorescent labels. Here we demonstrate technologies for measuring both the multiphoton excitation and emission properties of fluorescent labels at the 2200 nm window, using (1) 3-photon (ησ3) and 4-photon action cross sections (ησ4) and (2) 3-photon and 4-photon emission spectra both ex vivo and in vivo of quantum dots. Our results show that quantum dots have exceptionally large ησ3 and ησ4 for efficient generation of multiphoton fluorescence. Besides, the 3-photon and 4-photon emission spectra of quantum dots are essentially identical to those of one-photon emission, which change negligibly subject to the local environment of circulating blood. Based on these characterization results, we further demonstrate deep-brain vasculature imaging in vivo. Due to the superb multiphoton properties of quantum dots, 3-photon and 4-photon fluorescence imaging reaches a maximum brain imaging depth of 1060 and 940 μm below the surface of a mouse brain, respectively, which enables the imaging of subcortical structures. We thus fill the last gap in multiphoton fluorescence imaging in terms of wavelength selection.

 

Congratulations to Professor Ke Wang and co-authors from Shenzhen University and University of Chinese Academy of Sciences for their excellent work published in ACS Nano (IF=18.03)!

 

 

InvivoChem is proud to provide Professor Ke Wang’s team with our high-quality product Dexamethasone (DHAP) (Cat #: V1836; CAS #: 50-02-2, synthetic glucocorticoid, steroidal anti-inflammatory drug) and Carprofen (Cat #: V1074; CAS #: 53716-49-7, nonsteroid anti-inflammatory drug (NSAID)) for this research.

 

 

References: ACS Nano. 2023 Feb 28;17(4):3686-3695. doi: 10.1021/acsnano.2c10724.

Prev:Efficient NIR-II Type-I AIE Photosensitizer for Mitochondria-Targeted Photodynamic Therapy through Synergistic Apoptosis-Ferroptosis [ACS Nano (IF=18.03)!] by researchers from The Chinese University of Hong Kong Next:BLM overexpression as a predictive biomarker for CHK1 inhibitor response in PARP inhibitor-resistant BRCA-mutant ovarian cancer [Science Transl Med (IF=19.32)!] by researchers from National Institutes of Health (NIH), University of Washington and Cleveland Clinic, USA
Contact Us